← Back

Elekta AB ser. B

Elekta AB (publ) is a medical technology company that provides clinical solutions for treating cancer and brain disorders across the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Its offerings include linear machines and radiation therapy products such as Elekta Unity, Elekta Evo, Elekta Versa HD, Elekta Harmony, and Elekta Infinity, along with quality assurance and treatment and motion management solutions. The company also provides stereotactic radiosurgery products like Elekta Esprit and Elekta Care, brachytherapy products including Elekta Studio, ImagingRing, Oncentra Brachy, Venezia applicator, Elekta Flexitron afterloader, Elekta Geneva, and Elekta Xoft Axxent electronic brachytherapy systems, as well as the Leksell Vantage Stereotactic System, Elekta Kaiku, and veterinary radiation therapy solutions. Additionally, it offers Elekta Care 360, Elekta Care Learning, Elekta Care Community, and Elekta Partner Community. Elekta AB (publ) was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Price · split & dividend adjusted
News & notes moving 0O5H.LSE
SwedenUnited StatesChina
0O5H.LSE▼

Elekta Q1 Margins Improve but Sales Decline 2%

Elekta AB reported a 2% decline in net sales in constant exchange rates for the first quarter of fiscal 2027, with Solutions sales down 9% and Service sales up 5%, while adjusted gross margin improved to 42.6% from 37% a year earlier, including a SEK53 million positive impact from US tariff refunds. Adjusted EBIT margin reached 11.2%, and net income amounted to SEK261 million, with adjusted earnings per share of SEK0.69. Free cash flow improved by SEK154 million year-on-year to negative SEK266 million, and the book-to-bill ratio was 1.11 with order growth of 3%. The company reconfirmed its full-year outlook of 2% to 4% net sales growth in constant currency and an adjusted EBIT margin of 12.5% to 13.5%, despite headwinds from a stronger Swedish krona and higher tungsten prices. CEO Jakob Just-Bomholt noted solid double-digit order growth in the US following the Elekta Evo launch, while sales in China declined due to weak order intake from previous years, though the company expects solid revenue growth in the second quarter.
0O5H.LSE · Capital · Negative Q1 net sales declined 2% and Solutions sales fell 9%, though margins improved.
Read original ↗
GuruFocus·31dRead more →
Biotech & Genomic Medicine▲2

Radiotherapy Market to Reach USD 10.68 Billion by 2031 at 6.0% CAGR

The global radiotherapy market is projected to grow from USD 7.98 billion in 2026 to USD 10.68 billion by 2031, at a CAGR of 6.0%, according to a new report by MarketsandMarkets. Growth is driven by rising cancer incidence, increased healthcare investments, and demand for precision oncology, with rapid adoption of technologies such as proton beam therapy, adaptive radiotherapy, and AI-based treatment planning. The systems segment is expected to hold the largest share, while external beam radiotherapy dominates across technology, application, and procedure segments, and hospitals remain the leading end user. Asia Pacific is forecast to register the highest CAGR, supported by expanding oncology infrastructure and government spending in countries including China, India, and Japan. Key players include Siemens Healthineers AG, Elekta, Accuray Incorporated, IBA Worldwide, and ViewRay Technologies.
About megatrends
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Demand
0O5H.LSE · Demand · Positive Market growth forecast driven by rising cancer incidence and precision oncology demand, benefiting radiotherapy equipment makers like Elekta.
ARAY · Demand · Positive Market growth forecast driven by rising cancer incidence and precision oncology demand, benefiting radiotherapy equipment makers like Accuray.
SHL.XETRA · Demand · Positive Market growth forecast driven by rising cancer incidence and precision oncology demand, benefiting radiotherapy equipment makers like Siemens Healthineers.
Read original ↗
GlobeNewswire·76dRead more →